The Dreyer Peptide and Protein Sequencer

Credit: Courtesy of Alan Hawk / Historical Collections National Museum of Health and Medicine" /> Credit: Courtesy of Alan Hawk / Historical Collections National Museum of Health and Medicine As biochemists during the 1970s delved into the protein chemistry of cell signaling, cycling, and adhesion, they ran into two major obstacles: getting enough purified material for some proteins, and the low molecular weights of others. Interferon, for example, was so difficult to purify that it

Written byTerry Sharrer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As biochemists during the 1970s delved into the protein chemistry of cell signaling, cycling, and adhesion, they ran into two major obstacles: getting enough purified material for some proteins, and the low molecular weights of others. Interferon, for example, was so difficult to purify that it took more than two decades before its structural characterization. And tiny proteins like angiotensin II (8 amino acids) and the antidiuretic hormone vasopressin (9 amino acids) produced hard-to-interpret protein signatures.

Biochemists were constantly pushing the limits of technology to couple, cleave, extract, and sequence peptides with better sensitivity. Pehr Edman, in 1950, developed a chemical degradation process for amino acid sequencing and built the first automated "sequenator" for that task in 1967. Richard Laursen, at Boston University, improved on Edman's concept in 1971 by immobilizing the study sample on a resin support. This made it possible to investigate smaller peptides, but liquid solvents in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Accelerating Recombinase Reprogramming with Machine Learning

Accelerating Recombinase Reprogramming with Machine Learning

Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo

Products

waters-logo

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

zymo-research-logo

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-class Research

10x-genomics-logo

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA